Laboratory Data Integrity in FDA Warning Letters 2013

Recommendation
10/11 September 2025
Demonstrating the integrity and security of laboratory data, records, results and information is paramount for a successful audit or inspection for any GMP regulated quality control laboratory.
According to FDA's Pre Approval Inspection Program 7346.832, the FDA Inspector has to "audit the raw data, hardcopy or electronic, to authenticate the data submitted in the CMC section of the application. And to verify that all relevant data (e.g. stability, biobatch data) were submitted in the CMC section such that CDER product reviewers can rely on the submitted data as complete and accurate".
In the compilation of a few selected Warning Letters issued in 2013 you will find the key points regarding Laboratory Data Integrity.
The inspection focuses can be summarised and compiled in the following four themes:
1. Test Results / (Raw) Data
2. Written (Control) Procedures
3. Computerised Systems / Laboratory Instruments
4. Data Integrity Practices
Firms are responsible for the accuracy and integrity of all raw data generated in the analytical labs of the facilities. Records should demonstrate that each batch was tested and met the release specifications. These FDA Warning Letters indicate FDA's continued focus on data integrity as a central concern of its international inspection program.
Related GMP News
02.07.2025FDA Warning Letter: Missing Testing, No Stability Data, and Inadequate Raw Material Controls
25.06.2025FDA Warning Letter: "Memory-Based Manufacturing" and Lack of Analytical Testing
11.06.2025USP informs about Monographs affected by the Revision of NMR Chapters <761> and <1761>
28.05.2025FDA Warning Letter for Chinese Manufacturer: Inadequate Testing and Stability Program Deficiencies